Articles

Abstracted Scientific Content

Published on 19 December 2018

US generic prescription drug markets 2004‒2016

Submitted: 6 December 2018; Revised: 12 December 2018; Accepted: 14 December 2018; Published online first: 19 December 2018 Generic drugs are currently central to disease treatment in the US. However,...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0704.033

6.195 views

Read more →

Abstracted Scientific Content

Published on 03 December 2018

How does generic drug policy affect market prices?

Submitted: 21 November 2018; Revised: 22 November 2018; Accepted: 28 November 2018; Published online first: 4 December 2018 A study published by the World Health Organization (WHO) compares the effect...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0703.027

5.035 views

Read more →

Editor's Letter

Published on 03 December 2018

Latest features in GaBI Journal, 2018, Issue 3

This third issue of GaBI Journal in 2018 contains manuscripts which discuss a number of important, post-marketing, ‘real world’ generic and biosimilar medicinal product issues. In a Commentary, Pitts and...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2018.0703.020

2.809 views

Read more →

Thank you to reviewers

Published on 30 November 2018

Thank you to reviewers 2017

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.358 views

Read more →

Published on 05 September 2018

2018/2 GaBI Journal Table of Contents

Contents Editor’s Letter What to look forward to in GaBI Journal, 2018, Issue 2 Commentary Potential changes to the FDA approach to biosimilars have a global impact Original Research Patient-reported...

2.601 views

Read more →

Editor's Letter

Published on 27 August 2018

What to look forward to in GaBI Journal, 2018, Issue 2

The second issue of the 2018 GaBI Journal volume is being published at a time of increasing uncertainty concerning trade, tariffs, regulations as well as international and even inter-ally co-operation....

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2018.0702.010

3.098 views

Read more →

Abstracted Scientific Content

Published on 10 July 2018

EU risk-sharing agreements between 2000−2015

Submitted: 20 June 2018; Revised: 14 August 2018; Accepted: 18 August 2018; Published online first: 31 August 2018 The ageing population, longer life expectancies, and the increasing cost of drugs...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0703.026

3.757 views

Read more →

Review Article

Published on 10 July 2018

Are there biosimilar orphan drugs for Gaucher disease? An overview in Mexico

Author byline as per print journal: G Castañeda-Hernández, PhD; L Carbajal-Rodríguez, MD; M Cerón-Rodríguez, MD; Professor LC Correa-González, MD; A Esquivel-Aguilar, PhD; SJ Franco-Ornelas, MD; JE García Ortiz, PhD; CM...

Author(s): A Esquivel-Aguilar, PhD, CM Hernández-Guadarrama, MD, E Terreros-Muñoz, MD, G Castañeda-Hernández, JE García Ortiz, PhD, JI Navarrete-Martínez, MD, L Carbajal-Rodríguez, MD, M Cerón-Rodríguez, MD, Professor LC Correa-González, MD, SJ Franco-Ornelas, MD, Y Santillán-Hernández

biosimilar, Gaucher disease, imiglucerase, non-originator imiglucerase, orphan drugs

DOI: 10.5639/gabij.2019.0802.008

16.114 views

Read more →

Original Research

Published on 10 July 2018

Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina

Introduction and study objectives: Benefit-risk evaluations are essential throughout the life cycle of a drug to guarantee therapeutic efficacy for the authorized indications without an unacceptable incidence of adverse effects....

Author(s): Francisco Fernández, MD, Matías Deprati, MD, Patricia Rodríguez Acedo, Eduardo Spitzer, BSc, Alvaro Romera, MD, Nadia Español, BSc

adverse drug reaction, bevacizumab, biosimilar, monoclonal antibody, pharmacovigilance, safety profile

DOI: 10.5639/gabij.2018.0703.023

12.839 views

Read more →

Meeting Report

Published on 14 June 2018

First ASEAN educational workshop on regulation and approval of biosimilars/similar biotherapeutic products 2017 – Report

Author byline as per print journal: Robin Thorpe, PhD, FRCPath; Elwyn Griffiths, PhD, DSc; Niklas Ekman, PhD Abstract: Biosimilar medicines are being increasingly developed and used worldwide. Many regulatory agencies across...

Author(s): Elwyn Griffiths, DSc, PhD, Niklas Ekman, PhD, Robin Thorpe, PhD, FRCPath

ASEAN, biologicals, biosimilars, education, regulatory, similar biotherapeutic product

DOI: 10.5639/gabij.2018.0703.025

7.118 views

Read more →

Regulatory

Published on 14 June 2018

Biosimilar regulation and approval in Jordan

Author byline as per print journal: Rana Musa Ali Al-ali “Malkawi”, MSc; Wesal Salem Al Haqaish, BPharm; Hayel Obeidat, MD Abstract: The regulatory oversight of medicinal products in Jordan is...

Author(s): Hayel Obeidat, MD, Rana Musa Ali Al-ali “Malkawi”, MSc, Wesal Salem Al-haqaish, BPharm

biological, biosimilar, EMA, INN, Jordan FDA, regulation

DOI: 10.5639/gabij.2018.0702.016

11.357 views

Read more →

Commentary

Published on 14 June 2018

Medicines regulation in the MENA region and the importance of the World Health Organization’s INN proposal of Biological Qualifier

Author byline as per print journal: Peter J Pitts, BA; Michael S Reilly, Esq Abstract: The World Health Organization should finalize its Biological Qualifier guidance. Distinguishable naming will allow quick and...

Author(s): Michael S Reilly, Esq, Peter J Pitts, BA

Biological Qualifier (BQ), biosimilar, INN, medicines regulation, MENA (Middle East, North Africa), North Africa)

DOI: 10.5639/gabij.2018.0703.021

11.991 views

Read more →